


# BMJ Open Prevalence and factors associated with overweight and obesity among patients with type 2 diabetes mellitus in Uganda—a descriptive retrospective study

Salome Tino <sup>1</sup>, Billy N Mayanja,<sup>1</sup> Michael Charles Mubiru,<sup>2</sup> Emmanuel Eling,<sup>2</sup> Edward Ddumba,<sup>3</sup> Pontiano Kaleebu,<sup>1,4</sup> Moffat Nyirenda<sup>1,4</sup>

**To cite:** Tino S, Mayanja BN, Mubiru MC, *et al*. Prevalence and factors associated with overweight and obesity among patients with type 2 diabetes mellitus in Uganda—a descriptive retrospective study. *BMJ Open* 2020;**10**:e039258. doi:10.1136/bmjopen-2020-039258

► Prepublication history for this paper is available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2020-039258>).

Received 08 April 2020  
Revised 31 August 2020  
Accepted 04 October 2020



© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

<sup>1</sup>Non-Communicable Diseases, MRC/UVRI Uganda Research Unit On AIDS, Entebbe, Wakiso, Uganda

<sup>2</sup>Statistics, MRC/UVRI Uganda Research Unit On AIDS, Entebbe, Wakiso, Uganda

<sup>3</sup>Internal Medicine, Saint Raphael of Saint Francis Hospital Nsambya, Kampala, Uganda

<sup>4</sup>London School of Hygiene and Tropical Medicine, London, UK

## Correspondence to

Salome Tino;  
Tino.Salome@rcuganda.org

## ABSTRACT

**Objectives** To assess the prevalence and risk factors of overweight and obesity among type 2 diabetes mellitus (T2DM) patients in Uganda.

**Design** Retrospective chart review.

**Setting** This study was conducted in the outpatient's T2DM clinic in St. Francis Hospital—Nsambya, Uganda between March and May 2017.

**Participants** Type 2 diabetes patients registered in the diabetes clinic between July 2003 and September 2016.

**Outcome measures** Overweight and obesity defined as body mass index (kg/m<sup>2</sup>) of 25.0–29.9 and obesity as 30.0 or higher.

**Results** Of 1275 T2DM patients, the median age was 54 (IQR: 44–65) years, 770 (60.40%) were females, 887 (69.6%) had hypertension, 385 (28%) had controlled glycaemia, 349 (27%) were obese, while 455 (36%) were overweight. Overweight/obesity were lower among men (OR: 0.45, 95% CI: 0.340 to 0.593, p<0.001) and among patients aged ≥65 years (OR: 0.52, 95% CI: 0.350 to 0.770, p=0.001); patients who rarely ate fruits and vegetables (OR: 0.66, 95% CI: 0.475 to 0.921, p=0.014) but higher among patients of middle (OR: 1.83, 95% CI: 1.320 to 2.550, p<0.001) and upper (OR: 2.10, 95% CI: 1.450 to 2.990, p<0.001) socioeconomic status; on dual therapy (OR: 2.17, 95% CI: 1.024 to 4.604, p=0.043); with peripheral neuropathy (OR: 1.40, 95% CI: 1.039 to 1.834, p=0.026) and hypertension (OR: 1.70, 95% CI: 1.264 to 2.293, p<0.001).

**Conclusions** Overweight and obesity are high among T2DM patients in this population and may contribute significantly to poor outcomes of T2DM. Therefore, strategies to address this problem are urgently needed.

## INTRODUCTION

Overweight, defined as a body mass index (BMI) of 25.0–29.9 kg/m<sup>2</sup>, and obesity as BMI 30.0 kg/m<sup>2</sup> or above, represent progressive buildup of adipose tissue to levels that damage the physical and psychosocial health and well-being of an individual. Globally, the prevalence of obesity doubled in 73

## Strengths and limitations of this study

- This study is one of the first studies to report on the prevalence and factors associated with overweight and obesity among type 2 diabetes patients in Uganda.
- The use of patients' routine care data for this review has provided a large sample size which would not have been possible otherwise.
- The method used by the health facility to classify socioeconomic status and residence was not standardised and could have changed over the years.
- This study was conducted in outpatient diabetes clinics in a private not for profit facility and did not include those from public health facilities and the results may not be generalisable to the general population in Uganda.
- This operational programme data were not designed for research purposes, were not validated, had no quality checks done for completeness and plausibility and only limited number of variables were captured.

countries between 1980 and 2015, and in 2015 about 604 million adults were obese.<sup>1</sup> Overweight and obesity are a major threat to health, causing morbidity in over 2 billion people worldwide and accounting for at least 2.8 million (fifth leading cause) of deaths per year in adults.<sup>2</sup> Approximately, 44% of the burden of diabetes mellitus, 23% of the ischaemic heart disease and up to 41% of certain cancer are attributable to overweight and obesity.

The correlation between obesity and type 2 diabetes mellitus (T2DM) has been constantly proven and reproducibly observed in a wide range of studies across different populations.<sup>3–5</sup> Obesity is the most important risk factor for T2DM and has been postulated to be the major contributor to the current

epidemics of T2DM. Moreover, the presence of obesity among type 2 diabetes patients increases the risk of mortality from cardiovascular disease.<sup>46</sup> A meta-analysis of five longitudinal cohort studies demonstrated that overweight or obese diabetes patients had a twofold greater relative risk of mortality than normal-weight patients.<sup>7</sup> Obesity also promotes insulin resistance and metabolic syndrome whose other components besides hyperglycaemic are hypertension, dyslipidaemia, proinflammatory and prothrombotic state.<sup>8</sup> Overweight and obesity also increases the likelihoods of suboptimal glycaemic control making it difficult to achieve glycaemic targets.<sup>9</sup> As a result, the American Diabetes Association recommends and has developed guidelines for weight management in diabetic patients with overweight or obesity.<sup>10 11</sup>

Sub-Saharan Africa is experiencing a rapidly increasing burden of obesity, diabetes and other non-communicable diseases.<sup>12 13</sup> However, there are limited reliable data on the prevalence of obesity and how this contributes to the risk of T2DM in the region. A few studies indicate that overweight and obesity affects up to half of the type 2 diabetes patients, with prevalence varying according to age and setting; 85% in Tanzania<sup>14</sup> and 27.4%–83% in Nigeria.<sup>15 16</sup>

In Uganda, nationwide health and demographic surveys showed a significant rise in the prevalence of overweight (9.77% vs 16.21%) and obesity (1.99% vs 6.21%) in the general population between 1995 and 2016, respectively.<sup>17</sup> However, the prevalence of overweight and obesity among type 2 diabetes patient in Uganda is not known. This study was therefore undertaken to document the prevalence of overweight and obesity among type 2 diabetes patients, and the associated factors.

## METHODS

### Study design, setting and population

This descriptive retrospective study reviewed 2518 medical records of adult patients with T2DM who had registered at St. Francis Hospital Nsambya in Kampala-Uganda. The hospital is a private not for profit health facility which conducts a weekly diabetes mellitus clinic managing an average of 60 patients on every clinic day. During each clinic visit, trained nurses offer diabetes mellitus health education, biophysical and fasting blood glucose measurements are done prior to being reviewed by the doctors.<sup>18</sup> The study population consisted of T2DM patients registered at the clinic between July 2003 and September 2016. Patients clinic records (paper-based) were reviewed by a trained medical doctor, clinical officer and registered nurses between March and May 2017.

### Sample size and sampling procedure

To achieve a desired level of precision and a higher power all the 2518 patients registered in the T2DM clinic were considered. Consecutive convenience sampling method was used because of a substantial number of missing files and missing information. Patients whose records could

not be located, those with missing information including height and weight, type 1 diabetes mellitus or with gestational diabetes were excluded.

### Data source and collection

The data for this research were secondary data collected routinely in the hospital for patients' clinical monitoring and evaluation purposes. Data were abstracted from the hospital records and entered into a Microsoft Excel 2010 database (Microsoft Corp., Redmond, WA), checked for consistencies, outliers and completeness and then exported to STATA V.15 (Stata Corp, College Station, TX, USA) for further data cleaning, management and analysis. Data collected for this review included socio-demographics, medical history, glycaemic levels, medication use, complications of diabetes and biophysical measurements.

The primary outcome variable was overweight taken as a BMI of 25.0–29.9 kg/m<sup>2</sup>, and obesity as BMI 30.0 kg/m<sup>2</sup> or above.

### Clinical description of predictor and outcome variables

*BMI* was calculated as weight in kilograms divided by the square of height in metres (kg/m<sup>2</sup>). We used the WHO BMI (in kg/m<sup>2</sup>) definition as follows: normal weight: 18.0–24.9, overweight: 25.0–29.9 and obesity: 30.0 or higher.<sup>19</sup>

*Hypertension* was defined as systolic blood pressure  $\geq 140$  mm Hg and/or diastolic pressure of  $\geq 90$  mm Hg or on antihypertensive medication or a recorded diagnosis of hypertension.

*Optimal glycaemic control* was defined as preprandial glucose 4.4–7.2 mmol/L. Fasting glucose reading of  $>7.2$  mmol/L was considered as uncontrolled glycaemia among diabetes patients. Glucose reading was recorded as an average of the last three measurements on three separate clinic visits.

*Diabetes mellitus treatment options:* life style alone was defined as non-pharmacological treatment involving changes in diet and increased exercise; monotherapy as use of metformin only or any other single oral hypoglycemic; dual therapy as a combination of metformin and another oral hypoglycemic agent or metformin and insulin; triple therapy as a combination of metformin and two other oral hypoglycemic agents or metformin and another oral hypoglycemic plus insulin and combination injection therapy was defined as the use of different insulin regimens.

*Residence:* the host hospital's definitions were used; urban was defined as living within 1 km of a town council; peri-urban as living within 1 km of a shop selling soft drinks and rural as living more than 1 km of a shop selling soft drinks.

*Socioeconomic status (SES)* was defined based on household assets. Upper SES defined as living in a house with electricity or solar power supply, piped water, flushing toilet and kitchen inside; middle SES as living in a house with at least one but not all the utilities above; lower SES

as living in a house without the above and not mud or wattle and not grass hatched; poor SES as living in mud and wattle grass hatched house and none of the amenities above.

Potential confounders were age, sex, SES and residence.

### Statistical analysis

Statistical analysis was performed using STATA V.15 (Stata Corp, College Station, TX, USA). All variables were checked for missing data and inconsistencies. Distribution of the data using summary measures and graphical displays was examined to identify outliers and verified against source documentation. The patients' characteristics were summarised using means±SD or medians and percentages. The Kruskal-Wallis equality of proportions test was used to assess the association between participants age and the various BMI categories. Categorical variables were reported as numbers and percentages. Chi-square test ( $\chi^2$ ) was used to determine differences in prevalence of overweight and obesity and baseline characteristics of patients. Based on the  $\chi^2$  test and Kruskal-Wallis equality of proportions test, variables that were significantly associated ( $p < 0.05$ ) with the different BMI categories were used in the subsequent analysis.

Bivariate logistic regression analysis was used to determine whether patients' characteristics including age, sex, education, area of residence, hypertension, diabetes complications, diabetes treatment, smoking, socioeconomic status and participants adherence to study visits (lost to follow-up) were associated with overweight/obesity. Based on the results obtained from the bivariate logistic regression models, variables that were found to have an independent association, that is, gender/sex, education, area of residence, hypertension, fruit/vegetable intake, smoking, socioeconomic status, diabetes

complications and participant's adherence to study visits with the outcome in addition to age and diabetes treatment were added to the final multivariate logistic regression model. Age and diabetes treatment were added to this model based a priori knowledge of a known confounding effect of these variables with the outcome. From the unadjusted and adjusted models, p-values, OR and corresponding 95% CIs were reported.


### Results

#### Patients' characteristics and prevalence of overweight and obesity

Between July 2003 and September 2016, a total of 2518 diabetes mellitus patients were registered in the diabetes clinic of St. Francis Hospital Nsambya in Kampala, Uganda. We excluded 1243 (49.4%) records due to missing files, files with missing information/biophysical measurements, type 1 diabetes mellitus or gestational diabetes mellitus (figure 1). The median age at enrolment of the 1275 patients included in this analysis was 54 (IQR: 44–65) years. Most of the participants were female—770 (60.40%), majority lived in an urban setting—809 (63.45%) and 544 (42.7%) had attained at least primary level education. Of the 1275 participants, 349 (27%) were obese, 455 (36%) were overweight, 44 (3.5%) were underweight and 427 (33.5%) had normal BMI (table 1).

#### Factors associated with overweight/obesity

The factors found to be associated with overweight and obesity among T2DM patients were female gender, age, SES, fruit and vegetable intake, diabetes treatment options, neuropathy and hypertension (table 2). In general, the risk of being overweight or obese was lower in men than in women (OR: 0.45, 95% CI: 0.340 to 0.593,  $p < 0.001$ ). Among the different age categories, the highest



**Figure 1** Study organogram. BMI, body mass index; DM, diabetes mellitus.

**Table 1** Baseline characteristics of patients basing on BMI category

| Variable name/category                    | Overall<br>N (%) | Normal 18.5–24.9<br>N (%) | Underweight<br>below 18.5<br>N (%) | Overweight<br>25.0–29.9<br>N (%) | Obese<br>≥30<br>N (%) | P value       |
|---|------------------|---------------------------|------------------------------------|----------------------------------|-----------------------|---------------|
| <b>Sociodemographic characteristics</b>   |                  |                           |                                    |                                  |                       |               |
| <b>Gender</b>                             |                  |                           |                                    |                                  |                       |               |
| Female                                    | 770 (60.40)      | 208 (48.71)               | 20 (45.45)                         | 277 (60.88)                      | 265 (75.93)           | <0.001*       |
| Male                                      | 505 (39.60)      | 219 (51.29)               | 24 (54.55)                         | 178 (39.12)                      | 84 (24.07)            |               |
| <b>Median age (IQR) (years)</b>           | 54 (44–65)       | 55 (44–65)                | 44.5 (40.5–63)                     | 54 (44–64)                       | 53 (45–62)            | 0.268         |
| <b>Age group (years)</b>                  |                  |                           |                                    |                                  |                       |               |
| 19–44                                     | 326 (25.57)      | 108 (25.29)               | 20 (45.45)                         | 120 (26.37)                      | 78 (22.35)            | <b>0.003*</b> |
| 45–64                                     | 629 (49.33)      | 195 (45.57)               | 14 (31.82)                         | 224 (49.23)                      | 196 (56.16)           |               |
| Above 64                                  | 320 (25.10)      | 124 (29.04)               | 10 (22.73)                         | 111 (24.40)                      | 75 (21.49)            |               |
| <b>Residence</b>                          |                  |                           |                                    |                                  |                       |               |
| Rural                                     | 138 (10.82)      | 55 (12.88)                | 3 (6.82)                           | 53 (11.69)                       | 27 (7.74)             | 0.294         |
| Peri-urban                                | 328 (25.73)      | 110 (25.76)               | 14 (31.82)                         | 115 (25.27)                      | 89 (25.50)            |               |
| Urban                                     | 809 (63.45)      | 262 (61.36)               | 27 (61.36)                         | 287 (63.08)                      | 233 (66.76)           |               |
| <b>Education level</b>                    |                  |                           |                                    |                                  |                       |               |
| ≤Primary education                        | 544 (42.70)      | 175 (40.98)               | 18 (40.91)                         | 193 (42.42)                      | 158 (45.27)           | 0.608         |
| Secondary                                 | 460 (36.00)      | 151 (35.36)               | 15 (34.09)                         | 165 (36.26)                      | 129 (36.96)           |               |
| Postsecondary                             | 271 (21.30)      | 101 (23.63)               | 11 (25.00)                         | 97 (21.32)                       | 62 (17.77)            |               |
| <b>Socioeconomic status</b>               |                  |                           |                                    |                                  |                       |               |
| Lower                                     | 283 (22.20)      | 125 (29.27)               | 13 (29.55)                         | 83 (18.25)                       | 62 (17.77)            | <0.001*       |
| Middle                                    | 586 (45.96)      | 187 (43.79)               | 18 (40.91)                         | 221 (48.57)                      | 160 (45.85)           |               |
| Upper                                     | 406 (31.84)      | 115 (26.93)               | 13 (29.55)                         | 151 (33.19)                      | 127 (36.39)           |               |
| <b>Life style characteristics</b>         |                  |                           |                                    |                                  |                       |               |
| <b>Smoking</b>                            |                  |                           |                                    |                                  |                       |               |
| No  | 1137 (89.1)      | 370 (86.65)               | 38 (86.36)                         | 408 (89.67)                      | 320 (91.69)           | 0.136         |
| Yes                                       | 139 (10.9)       | 57 (13.35)                | 6 (13.64)                          | 47 (10.33)                       | 29 (8.31)             |               |
| <b>Fruit/vegetable intake</b>             |                  |                           |                                    |                                  |                       |               |
| Rarely                                    | 462 (38.12)      | 178 (43.95)               | 22 (50.00)                         | 154 (35.73)                      | 108 (32.53)           | <b>0.007*</b> |
| Once a week                               | 406 (33.50)      | 134 (33.09)               | 9 (20.45)                          | 145 (33.64)                      | 118 (35.54)           |               |
| Daily                                     | 344 (28.38)      | 93 (22.96)                | 13 (29.55)                         | 132 (330.63)                     | 106 (31.93)           |               |
| <b>Alcohol intake</b>                     |                  |                           |                                    |                                  |                       |               |
| No  | 909 (71.29)      | 319 (74.71)               | 29 (65.91)                         | 316 (69.45)                      | 245 (70.20)           | 0.260         |
| Yes                                       | 366 (28.71)      | 108 (25.29)               | 15 (34.09)                         | 139 (30.55)                      | 104 (29.80)           |               |
| <b>DM treatment characteristics</b>       |                  |                           |                                    |                                  |                       |               |
| Life style alone                          | 34 (2.69)        | 16 (3.79)                 | 1 (2.33)                           | 8 (1.66)                         | 9 (2.62)              | <b>0.002*</b> |
| Monotherapy                               | 292 (23.14)      | 113 (26.78)               | 8 (18.60)                          | 98 (21.63)                       | 73 (21.22)            |               |
| Dual therapy                              | 711 (56.34)      | 202 (47.87)               | 24 (55.81)                         | 281 (62.03)                      | 204 (59.30)           |               |
| Triple therapy                            | 109 (8.64)       | 38 (39.00)                | 2 (4.65)                           | 36 (7.95)                        | 33 (9.59)             |               |
| Combination injection therapy             | 116 (9.19)       | 53 (12.56)                | 8 (18.60)                          | 30 (6.62)                        | 25 (7.27)             |               |
| <b>DM complications and comorbidities</b> |                  |                           |                                    |                                  |                       |               |
| <b>Peripheral neuropathy</b>              |                  |                           |                                    |                                  |                       |               |
| No  | 795 (62.35)      | 293 (68.61)               | 28 (63.64)                         | 278 (61.10)                      | 196 (56.16)           | <b>0.004*</b> |
| Yes                                       | 480 (37.65)      | 134 (31.39)               | 16 (36.36)                         | 177 (38.90)                      | 153 (43.84)           |               |

Continued

Table 1 Continued

| Variable name/category                                 | Overall<br>N (%) | Normal 18.5–24.9<br>N (%) | Underweight<br>below 18.5<br>N (%) | Overweight<br>25.0–29.9<br>N (%) | Obese<br>≥30<br>N (%) | P value |
|--|------------------|---------------------------|------------------------------------|----------------------------------|-----------------------|---------|
| <b>Nephropathy</b>                                     |                  |                           |                                    |                                  |                       |         |
| No   | 1194 (93.65)     | 401 (93.91)               | 42 (95.45)                         | 422 (92.75)                      | 329 (94.27)           | 0.768   |
| Yes  | 81 (6.35)        | 26 (6.09)                 | 2 (4.55)                           | 33 (7.25)                        | 20 (5.73)             |         |
| <b>Retinopathy</b>                                     |                  |                           |                                    |                                  |                       |         |
| No   | 1019 (79.92)     | 349 (81.73)               | 38 (86.36)                         | 352 (77.36)                      | 280 (80.23)           | 0.274   |
| Yes  | 256 (20.08)      | 78 (18.27)                | 6 (13.64)                          | 103 (22.64)                      | 69 (19.77)            |         |
| <b>Macroangiopathy</b>                                 |                  |                           |                                    |                                  |                       |         |
| No   | 1246 (97.73)     | 416 (97.42)               | 43 (97.73)                         | 450 (98.90)                      | 337 (96.56)           | 0.162   |
| Yes  | 27 (2.27)        | 11 (2.58)                 | 1 (2.27)                           | 5 (1.10)                         | 12 (3.44)             |         |
| <b>Cerebrovascular accident</b>                        |                  |                           |                                    |                                  |                       |         |
| No   | 1261 (98.90)     | 422 (98.83)               | 44 (100)                           | 451 (99.12)                      | 344 (98.57)           | 0.784   |
| Yes  | 14 (1.10)        | 5 (1.17)                  | 0 (0)                              | 4 (0.88)                         | 5 (8.43)              |         |
| <b>Hypertension</b>                                    |                  |                           |                                    |                                  |                       |         |
| No   | 388 (30.40)      | 160 (37.50)               | 22 (50.00)                         | 127 (27.90)                      | 79 (22.60)            | <0.001* |
| Yes  | 887 (69.60)      | 267 (62.50)               | 22 (50.00)                         | 328 (72.10)                      | 270 (77.40)           |         |
| <b>Glycaemic control (n=1234)</b>                      |                  |                           |                                    |                                  |                       |         |
| Hypoglycaemic  | 18 (1.46)        | 9 (2.20)                  | 1 (2.38)                           | 4 (0.90)                         | 4 (1.18)              | 0.509   |
| Optimal glycaemic control                              | 326 (26.42)      | 103 (25.18)               | 11 (26.19)                         | 113 (25.51)                      | 99 (29.12)            |         |
| Uncontrolled glycaemia                                 | 890 (72.12)      | 297 (72.6)                | 30 (71.43)                         | 326 (73.59)                      | 237 (69.71)           |         |
| <b>Erectile dysfunction (n=505)</b>                    |                  |                           |                                    |                                  |                       |         |
| No   | 396 (78.42)      | 176 (80.37)               | 22 (91.69)                         | 131 (73.60)                      | 67 (79.76)            | 0.150   |
| Yes  | 109 (21.58)      | 43 (19.63)                | 2 (8.33)                           | 47 (26.40)                       | 17 (20.24)            |         |
| <b>Lost to follow-up<br/>(≥6 months consecutively)</b> |                  |                           |                                    |                                  |                       |         |
| No   | 108 (8.5)        | 23 (5.39)                 | 1 (2.27)                           | 46 (10.11)                       | 38 (10.89)            | 0.009*  |
| Yes  | 1167 (91.53)     | 404 (94.61)               | 43 (97.73)                         | 409 (89.89)                      | 311 (89.11)           |         |

\*Statistically significant at level  $p < 0.05$ .

BMI, body mass index; DM, diabetes mellitus.

prevalence of overweight/obesity was between the age of 45 and 65 years; those age 65 years and more had the least risk (OR: 0.52, 95% CI: 0.350 to 0.770,  $p=0.001$ ). Middle and upper SES were associated with increased risk of obesity and overweight (OR: 1.83, 95% CI: 1.320 to 2.550,  $p \leq 0.001$ ) and (OR: 2.10, 95% CI: 1.450 to 2.990,  $p < 0.001$ ), respectively. Intriguingly, those who reported to rarely consuming fruits and vegetables were less likely to be overweight or obese than those who had regular intake of fruits and vegetables (OR: 0.66, 95% CI: 0.475 to 0.921,  $p=0.014$ ). Patients who were on dual therapy were more than 2.2 times more likely to be overweight and obese (OR: 2.17, 95% CI: 1.024 to 4.604 and  $p=0.043$ ). Patients who had neuropathy complications were 1.4 times more likely to be overweight and obese (OR: 1.40, 95% CI: 1.039 to 1.834,  $p=0.026$ ). Diabetic patients who also had hypertension were more than 1.7 times more

likely to be overweight or obese (OR: 1.70, 95% CI: 1.264 to 2.293,  $p < 0.001$ ) (table 2).

## Discussion

In this study, we observed nearly 65% of patients with T2DM were either overweight or obese. The prevalence was particularly high among female patients, those with middle or higher SES, between 40 and 65 years of age, on multiple antidiabetic drugs and those with comorbidity or complications.

The prevalence of overweight and obesity among type 2 diabetes patients in this study was markedly higher than the 24.8% found in the general (non-diabetic) population in Eastern Uganda in 2013,<sup>20</sup> but was consistent with data from other settings which showed high levels of overweight and obesity among T2DM patients. Indeed, high prevalence has been reported in higher income countries. For

**Table 2** Unadjusted and adjusted logistic regression model of overweight and obesity among type 2 diabetic patients in St. Francis Hospital Nsambya

| Variable                          | Unadjusted model |                |         | Adjusted model |                |         |
|-----------------------------------|------------------|----------------|---------|----------------|----------------|---------|
|                                   | OR               | 95% CI         | P value | OR             | 95% CI         | P value |
| <b>Sex</b>                        |                  |                |         |                |                |         |
| Female                            | Ref              |                |         |                |                |         |
| Male                              | 1.60             | 1.092 to 2.4   | 0.017*  | 0.45           | 0.340 to 0.593 | <0.001* |
| <b>Age (years)</b>                |                  |                |         |                |                |         |
| 19–44                             | Ref              | Ref            |         | Ref            | Ref            |         |
| 45–64                             | 1.20             | 0.879 to 1.569 | 0.275   | 0.86           | 0.620 to 1.190 | 0.356   |
| 65+                               | 0.81             | 0.590 to 1.134 | 0.228   | 0.52           | 0.353 to 0.770 | 0.001*  |
| <b>Lost to follow-up</b>          |                  |                |         |                |                |         |
| No                                | Ref              | Ref            |         | Ref            | Ref            |         |
| Yes                               | 0.49             | 0.303 to 0.786 | 0.003*  | 0.68           | 0.400 to 1.150 | 0.150   |
| <b>Socioeconomic status</b>       |                  |                |         |                |                |         |
| Lower                             | Ref              | Ref            |         | Ref            | Ref            |         |
| Middle                            | 1.76             | 1.305 to 2.362 | <0.001* | 1.83           | 1.320 to 2.550 | <0.001* |
| Upper                             | 2.10             | 1.508 to 2.879 | <0.001* | 2.10           | 1.452 to 2.994 | <0.001* |
| <b>Smoking status</b>             |                  |                |         |                |                |         |
| No                                | Ref              | Ref            |         | Ref            | Ref            |         |
| Yes                               | 0.68             | 0.470 to 0.976 | 0.037*  | 0.99           | 0.643 to 1.490 | 0.920   |
| <b>Fruit and vegetable intake</b> |                  |                |         |                |                |         |
| Daily                             | Ref              | Ref            |         | Ref            | Ref            |         |
| Once a week                       | 0.77             | 0.558 to 1.053 | 1.101   | 0.87           | 0.619 to 1.227 | 0.432   |
| Rarely                            | 0.58             | 0.423 to 0.781 | <0.001* | 0.66           | 0.475 to 0.921 | 0.014*  |
| <b>Treatment of diabetes</b>      |                  |                |         |                |                |         |
| Exercise and diet alone           | Ref              | Ref            |         | Ref            | Ref            |         |
| Monotherapy                       | 1.42             | 0.691 to 2.934 | 0.338   | 1.40           | 0.644 to 3.017 | 0.43    |
| Dual therapy                      | 2.26             | 1.120 to 4.560 | 0.023*  | 2.17           | 1.024 to 4.604 | 0.043*  |
| Triple therapy                    | 1.71             | 0.776 to 3.763 | 0.183   | 1.43           | 0.613 to 3.334 | 0.407   |
| Combination injection therapy     | 0.98             | 0.448 to 2.130 | 0.953   | 0.96           | 0.414 to 2.204 | 0.914   |
| <b>Complications of diabetes</b>  |                  |                |         |                |                |         |
| Peripheral neuropathy             |                  |                |         |                |                |         |
| No                                | Ref              | Ref            |         | Ref            | Ref            |         |
| Yes                               | 1.52             | 1.188 to 1.951 | 0.001   | 1.40           | 1.039 to 1.834 | 0.026*  |
| <b>Hypertension</b>               |                  |                |         |                |                |         |
| No                                | Ref              | Ref            |         | Ref            | Ref            |         |
| Yes                               | 1.74             | 1.352 to 2.237 | <0.001* | 1.70           | 1.264 to 2.293 | <0.001* |

\*Indicating significant values based on  $\chi^2$  value p-value <0.05.

Ref, reference category; .

example, in the UK, approximately 86%–90% of patients with T2DM had BMI $\geq$ 25;<sup>21 22</sup> in Australia, 53% were obese and 32.8% were overweight;<sup>23</sup> in Saudi Arabia, 87.5% had BMI $\geq$ 25 with the prevalence being higher among females (87.7%) than males (83.1%).<sup>24</sup> Although data from sub-Saharan Africa are limited, varying rates have been observed in Ethiopia (40%),<sup>25</sup> Tanzania (85.0%),<sup>14</sup> Nigeria (27.4%–83%)<sup>15 16</sup> and Sudan (64.4%).<sup>26</sup> It is likely that with the current trends towards urbanisation and globalisation and adoption of associated behaviours (eating habits and

reduced physical activity), the prevalence of overweight and obesity in sub-Saharan Africa, including among patients with T2DM, will increase sharply<sup>27</sup>—with a parallel increase in complications such as cardiovascular diseases. Unlike in high-income countries where overweight and obesity are common among individuals with lower SES, in sub-Saharan Africa, the prevalence is higher among the educated and affluent and higher BMI has a number of positive social connotations.<sup>28</sup>

As with other studies in the region, our study showed that overweight and obesity among T2DM patients were more common among women. The reasons for this are not fully understood, but may relate to social drivers as well as biological factors.<sup>29</sup> Nonetheless, as associations with age, education and SES, these findings underscore the importance of understanding the local context when designing potential interventions to target at risk groups.

Intriguingly, in our study, we found that patients who rarely took fruits and vegetables were less likely to be overweight or obese compared with those ate fruits and vegetables daily. The reasons for this discrepancy are unclear; it might relate to unreliability of self-reported data. It is also possible that this is a reflection of SES—individuals with higher SES are likely to eat more vegetables, but are also more likely to be overweight or obese because of other dietary habits and/or other behaviours (such as physical inactivity). Indeed, most studies have shown that for increased fruit and vegetable intake to be successful in controlling overweight and obesity, it needs to be combined with other weight loss programmes like advice to reduce energy intake.<sup>30</sup>

T2DM patients who were on more than one antidiabetic agent were twice more likely to be overweight and obese. The majority of these patients were on thiazolidinediones and sulphonylureas which, together with insulin, cause weight gain. This makes it difficult to determine how much of the excessive body weight was primary and how much was due to the effect of medication. Findings from other studies have shown that secretagogues which include sulphonylureas (glyburide, glipizide and glimepiride), insulin and thiazolidinediones cause weight gain of 2–3 kg,<sup>31</sup> of up to 1.8 kg<sup>32</sup> and 1.5–4 kg,<sup>33 34</sup> respectively.

The association between overweight or obese and diabetic complications has also been reported in other studies, such as the KORA study and the National Health and Nutrition Examination Survey III where overweight and obesity among diabetes patients were associated with diabetic peripheral neuropathy.<sup>35 36</sup> Similarly, a number of studies have document associations between hypertension and overweight and/or obesity among T2DM patients,<sup>37–40</sup> perhaps reflecting clustering of components of the metabolic syndrome.<sup>37 41</sup>

### Study strengths

To our understanding, this study is one of the first studies to report on the prevalence and factors associated with overweight and obesity among type 2 diabetes patients receiving diabetes care in a private not for profit health facility in Uganda. Determining the prevalence of overweight and obesity among type 2 diabetes patients is important as these are directly related to increased morbidity and mortality among diabetes patients as well as in the general population. The use of patients' routine care data over a 13-year period for this review has provided us with a large sample size which would not have been feasible otherwise.

### Study limitations

Our study findings might have been affected by a selection bias and thus may not be generalisable to all type 2 diabetes patients as we have not included those who sought care from public non-paying health facilities. As with most clinic care records, the quality of data recorded is usually less satisfactory for research purposes, and in our case, the incomplete and missing data on weight and height might have biased our findings. Additionally, these operational programme data were not designed for research purposes, thus was not validated, had no quality checks done for completeness and plausibility and we were only able to look at a limited number of variables documented in the patient's charts. Due to the changes in the general economic status in the country, the patients' economic status might have changed over the 13-year duration of the study from what it was at registration in the clinic. The method used by the health facility to classify SES and residence were not standardised and could have changed over the years.

### CONCLUSION

Overweight and obesity were high among T2DM patients in this population and may contribute significantly to the burden and poor outcomes of T2DM. Female gender, middle and higher SES, age between 40 and 60 years, being on multiple antidiabetic drugs and having comorbidity or complications were associated with overweight and obesity. Appropriate control strategies to improve nutrition and promote weight loss are urgently needed to mitigate this increasing health challenge.

**Acknowledgements** We acknowledge the Diabetes study team, and Statistics team, staff of St. Francis Hospital Nsambya and the MRC/UVRI and LSHTM Uganda Research Unit. We acknowledge the input of Isaac Sekitoleko in revising the statistical analysis section. Diabetes study team: Clara Wekesa, Salome Tino, Bengo Samuel, Kigongo Aisha, Rose Nabwatwo, Anthony Makhoba, Raymond Mwebaze, Edward Ddumba, Billy N. Mayanja, Pontiano Kaleebu, Rob Newton and Moffat Nyirenda.

**Contributors** All authors conceived and designed the study. ST, MCM and EE participated in data collection and MCM conducted data analysis. ST, BNM and MN interpreted and wrote the original manuscript draft; ED, PK and MN revised the initial draft and all authors revised and approved the final version of the paper.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.

**Patient consent for publication** Not required.

**Ethics approval** This study was nested within the bigger H3A Diabetes Multicentre study whose main aim was to assess the prevalence, environmental and genetic determinants of type 2 diabetes in sub-Saharan Africa. This study received approval from Uganda Virus Research Institute Research and Ethics Committee, reference number: UVRI REC 456, the Uganda National Council for Science and Technology, reference number: UNCST HS 1671, and administrative clearance was obtained from the Research Ethics Committee of St. Francis Hospital Nsambya. Patient's names were not included in the data extraction forms and the study was conducted in accordance with ethical principles and confidentiality was ensured throughout the study.

**Provenance and peer review** Not commissioned; externally peer reviewed.



**Data availability statement** Data are available upon reasonable request. Availability of data and materials. Data will not be shared publicly due to the data sharing policy of the MRC/UVRI and LSHTM Uganda Research Unit, which requires a prior data sharing agreement. However, the study protocol and a full data set containing the data supporting the study findings in this report can be obtained from the Unit Director, by email to: [mrc@mrcuganda.org](mailto:mrc@mrcuganda.org) or the corresponding author. More clarification on this can be accessed through this website: <https://www.mrcuganda.org/publications/data-sharingpolicy>

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

#### ORCID iD

Salome Tino <http://orcid.org/0000-0001-8584-877X>

## REFERENCES

- Afshin A, Forouzanfar MH, Reitsma MB, GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. *N Engl J Med* 2017;377:13–27.
- Awosan, KJ, Ibrahim, MTO, Essien, E, et al. Dietary pattern, lifestyle, nutrition status and prevalence of hypertension among traders in Sokoto central market, Sokoto, Nigeria. *Int J Nutr Metab* 2014;6:9–17.
- Wang S, Ma W, Yuan Z, et al. Association between obesity indices and type 2 diabetes mellitus among middle-aged and elderly people in Jinan, China: a cross-sectional study. *BMJ Open* 2016;6:e012742.
- Han SJ, Boyko EJ. The evidence for an obesity paradox in type 2 diabetes mellitus. *Diabetes Metab J* 2018;42:179–87.
- Eckel RH, Kahn SE, Ferrannini E, et al. Obesity and type 2 diabetes: what can be unified and what needs to be individualized? *Diabetes Care* 2011;34:1424–30.
- Czernichow S, Kengne A-P, Huxley RR, et al. Comparison of waist-to-hip ratio and other obesity indices as predictors of cardiovascular disease risk in people with type-2 diabetes: a prospective cohort study from advance. *Eur J Cardiovasc Prev Rehabil* 2011;18:312–9.
- Gao F, Wang ZJ, Shen H, et al. Impact of obesity on mortality in patients with diabetes: meta-analysis of 20 studies including 250,016 patients. *J Diabetes Investig* 2018;9:44–54.
- Grundy SM, Brewer HB, Cleeman JI, et al. Definition of metabolic syndrome. *Circulation* 2004;109:433–8.
- Bae JP, Lage MJ, Mo D, et al. Obesity and glycemic control in patients with diabetes mellitus: analysis of physician electronic health records in the US from 2009–2011. *J Diabetes Complications* 2016;30:212–20.
- American Diabetes Association. 8. Obesity Management for the Treatment of Type 2 Diabetes: *Standards of Medical Care in Diabetes-2019*. *Diabetes Care* 2019;42:S81–9.
- Lau DCW, Teoh H. Benefits of modest weight loss on the management of type 2 diabetes mellitus. *Can J Diabetes* 2013;37:128–34.
- Biadgilign S, Mgutshini T, Haile D, et al. Epidemiology of obesity and overweight in sub-Saharan Africa: a protocol for a systematic review and meta-analysis. *BMJ Open* 2017;7:e017666.
- Charles A, Boatemaa S, Frempong G. *Obesity in Sub-Saharan Africa*. Springer, 2015: 1–13.
- Damian DJ, Kimaro K, Mselle G, et al. Prevalence of overweight and obesity among type 2 diabetic patients attending diabetes clinics in northern Tanzania. *BMC Res Notes* 2017;10:515.
- Gezawa ID, Uloko AE, Gwaram BA, et al. Pattern of obesity among patients with type 2 diabetes at a tertiary healthcare center in northern Nigeria. *Diabetes Metab Syndr Obes* 2019;12:2785–90.
- Fadupin GT, Joseph EU, Keshinro OO. Prevalence of obesity among type 2 diabetics in Nigeria a case study of patients in Ibadan, Oyo state, Nigeria. *Afr J Med Med Sci* 2004;33:381–4.
- pp.Yaya S, Ghose B. Trend in overweight and obesity among women of reproductive age in Uganda: 1995–2016. *Obes Sci Pract* 2019;5:312–23.
- Kibirige D, Atuhe D, Sebuya R, et al. Suboptimal glycaemic and blood pressure control and screening for diabetic complications in adult ambulatory diabetic patients in Uganda: a retrospective study from a developing country. *J Diabetes Metab Disord* 2014;13:40.
- WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *Lancet* 2004;363:157–63.
- Kirunda BE, Fadnes LT, Wamani H, et al. Population-based survey of overweight and obesity and the associated factors in peri-urban and rural eastern Uganda. *BMC Public Health* 2015;15:1168.
- Daousi C, Casson IF, Gill GV, et al. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. *Postgrad Med J* 2006;82:280–4.
- Whitmore C. Type 2 diabetes and obesity in adults. *Br J Nurs* 2010;19:880–6.
- Thomas MC, Zimmet P, Shaw JE. Identification of obesity in patients with type 2 diabetes from Australian primary care: the NEFRON-5 study. *Diabetes Care* 2006;29:2723–5.
- Abed Bakhotmah B. Prevalence of obesity among type 2 diabetic patients: non-smokers housewives are the most affected in Jeddah, Saudi Arabia. *Open J Endocr Metab Dis* 2013;03:25–30.
- Kiros KG, Abyu GY, Belay DS, et al. Magnitude of overweight and associated factors among type 2 diabetes mellitus patients at Mekelle public hospitals, Tigray, Ethiopia: a cross-sectional study. *BMC Res Notes* 2019;12:762.
- Ali YA, Almobarak AO, Awadalla H, et al. Obesity among Sudanese adults with diabetes: a population-based survey. *Ann Transl Med* 2017;5:5.
- Hillier TA, Pedula KL. Characteristics of an adult population with newly diagnosed type 2 diabetes: the relation of obesity and age of onset. *Diabetes Care* 2001;24:1522–7.
- Renzaho AMN. Fat, rich and beautiful: changing socio-cultural paradigms associated with obesity risk, nutritional status and refugee children from sub-Saharan Africa. *Health Place* 2004;10:105–13.
- Rasmussen KM, Yaktine AL. *Determinants of gestational weight gain, weight gain during pregnancy: reexamining the guidelines*. US: National Academies Press, 2009.
- Rolls BJ, Ello-Martin JA, Tohill BC. What can intervention studies tell us about the relationship between fruit and vegetable consumption and weight management? *Nutr Rev* 2004;62:1–17.
- Marbury T, Huang WC, Strange P, et al. Repaglinide versus glyburide: a one-year comparison trial. *Diabetes Res Clin Pract* 1999;43:155–66.
- Dailey G, Admane K, Mercier F, et al. Relationship of insulin dose, A1c lowering, and weight in type 2 diabetes: comparing insulin Glargine and insulin detemir. *Diabetes Technol Ther* 2010;12:1019–27.
- Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The pioglitazone 001 Study Group. *Diabetes Care* 2000;23:1605–11.
- McFarlane SI. Antidiabetic medications and weight gain: implications for the practicing physician. *Curr Diab Rep* 2009;9:249–54.
- Oh TJ, Lee J-E, Choi SH, et al. Association between body fat and diabetic peripheral neuropathy in middle-aged adults with type 2 diabetes mellitus: a preliminary report. *J Obes Metab Syndr* 2019;28:112–7.
- Ylitalo KR, Sowers M, Heeringa S. Peripheral vascular disease and peripheral neuropathy in individuals with cardiometabolic clustering and obesity. *Diabetes Care* 2011;34:1642.
- Hall JE, do Carmo JM, da Silva AA, et al. Obesity-Induced hypertension: interaction of neurohumoral and renal mechanisms. *Circ Res* 2015;116:991–1006.
- Leggio M, Lombardi M, Caldarone E, et al. The relationship between obesity and hypertension: an updated comprehensive overview on vicious twins. *Hypertens Res* 2017;40:947–63.
- Hall JE. The kidney, hypertension, and obesity. *Hypertension* 2003;41:625–33.
- Landsberg L, Aronne LJ, Beilin LJ, et al. Obesity-Related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of the obesity Society and the American Society of hypertension. *J Clin Hypertens* 2013;15:14–33.
- Jiang S-Z, Lu W, Zong X-F, et al. Obesity and hypertension. *Exp Ther Med* 2016;12:2395–9.